Rikard Pehrson

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

Journal: Journal of medicinal chemistry

Published: July 11, 2026

Discovery of a Selective Histone Deacetylase 6 Degrader (HDAC6 PROTAC) with a Short and Rigid Linker Demonstrating Sustained Knockdown of HDAC6 In Vivo.

Discovery of a Selective Histone Deacetylase 6 Degrader (HDAC6 PROTAC) with a Short and Rigid Linker Demonstrating Sustained Knockdown of HDAC6 In Vivo.

Journal: ACS medicinal chemistry letters

Published: February 11, 2026

Topical BET PROTACs for locally restricted protein degradation in the lung.

Topical BET PROTACs for locally restricted protein degradation in the lung.

Journal: RSC medicinal chemistry

Published: February 24, 2025

RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.

RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.

Journal: PloS one

Published: January 23, 2024

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

Journal: Journal of medicinal chemistry

Published: August 31, 2021

Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.

Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.

Journal: British journal of clinical pharmacology

Published: December 06, 2019

AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure.

AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure.

Journal: The Journal of pharmacology and experimental therapeutics

Published: December 06, 2017

An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

Journal: British journal of clinical pharmacology

Published: March 22, 2016

Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.

Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: August 18, 2014

Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs.

Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs.

Journal: Journal of pharmacological and toxicological methods

Published: July 03, 2013

The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogs.

The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogs.

Journal: Journal of pharmacological and toxicological methods

Published: October 16, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026